News: Baby teeth could be rich stem cell source
02 June, 2004 by Graeme O'NeillIn future, the tooth fairy may leave children something more than a silver coin in a glass of water, in exchange for their lost milk teeth. Researchers at the Hanson Institute in Adelaide believe pluripotent stem cells from those deciduous teeth could help sustain their owners’ dental, skeletal, neural and cardiovascular health well into the autumn of their lives.
News: Using stem cells to grow organs organically
02 June, 2004 by Graeme O'NeillAustralian scientists believe it may be possible to grow replacement organs organically, by providing organ-building stem cells with a 3D template and leaving them to grow in situ, within the patient’s own body.
News: Researchers dig into Top End soil
02 June, 2004 by Susan WilliamsonA team at CSIRO Tropical Ecosystems Research Centre in Darwin is getting an insight into how soil macro-invertebrates like termites, worms and ants help to maintain healthy country in the tropics.
Biocatalysis: the next molecular biology revolution
02 June, 2004 by Susan WilliamsonThe biocatalysis group at CSIRO Molecular Science, led by Prof Michael Zachariou, has established an impressive pipeline of research and is working towards developing a more sustainable and renewable chemical industry in Australia, writes Susan Williamson.
Beam me up: the Synchotron is on its way
27 May, 2004 by Melissa TrudingerMedical researchers in Melbourne were given a brief glimpse this week of the potential of the synchrotron to enhance and expand medical science.
Renowned polymer chemist to join Bio21
10 May, 2004 by Melissa TrudingerExpatriate Australian polymer chemist Prof Andrew Holmes is set to join Melbourne's Bio21 Institute of Molecular Science and Biotechnology in October.
Stem Cell Centre relieved by fed funding top-up
10 May, 2004 by Melissa TrudingerThe National Stem Cell Centre has received a substantial boost in the form of an extra AUD$55 million in federal government funding to support it through the period 2006-2011.
Further studies planned into J&J and Amgen anaemia drug risks
05 May, 2004 by ReutersA US advisory panel has voiced support for further research to determine whether widely used anaemia drugs sold by Johnson & Johnson and Amgen might stimulate tumour growth.
Singapore's Cordlife sets up CyGenics, plans Australian capital raising
23 April, 2004 by Renate KrelleSingapore-based Cordlife has created a holding company, CyGenics, which will be based in Melbourne, and revealed plans to raise up to $20 million in funding.
Select Vaccines aiming to raise $1.8m
20 April, 2004 by Melissa TrudingerSelect Vaccines (ASX:SLT) is planning to raise up to AUD$1.8 million in a private placement to support its R&D programs.
Long journey, but Living Cell Technologies finally nears market
20 April, 2004 by Melissa TrudingerCell therapy company Living Cell Technologies (LCT) is planning to list on the ASX in the next few months, after completing a rights issue which will provide it with AUD$4.8 million cash and the ability to upgrade from its current listing on the Newcastle Stock Exchange (NSX:LCT).
Stem Cell Sciences relocates to Scotland
19 April, 2004 by Graeme O'NeillSome tartan-clad angels -- and a need to be closer to European customers -- are behind a decision by Melbourne-born company Stem Cell Sciences to relocate its headquarters to Edinburgh.
Psivida earns new European patent
15 March, 2004 by Graeme O'NeillPerth-based biotech-nanotech company pSivida (ASX:PSD) announced today that its UK subsidiary PsiMedica has been granted the latest in a series of European patents on its proprietary biocompatible-biodegradable silicon technology, BioSilicon.
Stem cell research offers hope for baldness cure
15 March, 2004 by Staff WritersHair follicles may carry a special type of cell that has the potential to grow into various types of tissue, a finding that could lead scientists closer to a cure for baldness, according to US dermatologists.
First patent granted to Norwood Immunology
17 February, 2004 by Melissa TrudingerNorwood Abbey (ASX:NAL) subsidiary Norwood Immunology has been granted its first patent, covering the use of GnRH analogues to increase the T cell population for the treatment of a variety of diseases.
